Erratum: Efficacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: Preclinical evaluation in rabbits and Rhesus monkeys (Biotechnology Journal (2009) vol. 4 (391-399) 10.1002/biot.200800213);Efficacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: Preclinical evaluation in rabbits and Rhesus monkeys

Biotechnology Journal

Volumn 4, Issue 3, 2009, Pages 391-399

  Chawla, Anil ^a   Midha, Shuchi ^b   Bhatnagar, Rakesh ^b  

^a Panacea Biotec Ltd   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Anthrax; Protective antigen; Recombinant vaccine

Indexed keywords

AEROSOLS; ANTIGENS; DISEASES; ESCHERICHIA COLI; MAMMALS; VACCINES;

ANTHRAX; BACILLUS ANTHRACIS SPORES; NEUTRALIZING ANTIBODIES; NEW ZEALAND WHITE RABBIT; PROTECTIVE ANTIGENS; PROTECTIVE EFFICACY; QUALITATIVE DIFFERENCES; RECOMBINANT VACCINES;

BACTERIOLOGY;

ANTHRAX VACCINE; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; IMMUNOGENICITY; LD 50; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVACCINATION; RHESUS MONKEY;

ANIMALIA; BACILLUS ANTHRACIS; ESCHERICHIA COLI; LAGOMORPHA; MACACA; MACACA MULATTA; ORYCTOLAGUS CUNICULUS; PRIMATES;

EID: 64549109852     PISSN: 15420752     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.200990051     Document Type: Erratum

References (28)

1. Guidi-Rontani, C., Weber-Levy, M., Labruyere, E., Mock, M., Germination of Bacillus anthracis spores within aveolar macrophages. Mol. Microbiol. 1999, 31, 9-17.
2. Mock, M., Fouet, A., Anthrax. Annu. Rev. Microbiol. 2001, 55, 647-671.
3. Jernigan, J. A., Stephens, D. S., Ashford, D. A., Omenaca, C. et al., Anthrax Bioterrorism Investigation Team Bioterrorismrelated inhalational anthrax: The first 10 cases reported in the United States. Emerg. Infect. Dis. 2001, 7, 933-944.
4. Inglesby, T.V., Henderson, D. A., Bartlett, J. G., Ascher, M. S. et al., Anthrax as a biological weapon: Medical and public health management. JAMA 1999, 281, 1735-1745.
5. Puziss, M., Wight, G.G., Studies on immunity in anthrax. Gel adsorbed protective antigen for immunization of man. J. Bacteriol. 1962, 85, 230-236.
6. Whiting, G. C., Rijpkema, S., Adams, T., Corbel, M. J., Characterization of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Vaccine 2004, 22, 4245-4251.
7. Fellows, P. F., Linscott, M. K., Ivins, B. E., Pitt, M. L. M. et al., Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and Rhesus Macaques against a challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001, 19, 3241-3247.
8. Friedlander, A. M., Pittman, R. R., Parker, G.W., Evidence for safety and efficacy against inhalational anthrax. JAMA 1999, 282, 2104-2106.
9. Gupta, P., Waheed, S. M., Bhatnagar, R., Expression and purification of the recombinant protective antigen of Bacillus anthracis. Protein Exp. Purif. 1999, 16, 369-376.
10. McBride, B.W., Mogg, A., Telfer, J. L., Lever, M. S. et al., Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 1998, 16, 810-817.
11. Ivins, B. E., Fellows, P. F., Pitt, M. L. M., Estep, J. E. et al., Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in Rhesus monkeys. Salisbury Med. Bull. (Special Suppl) 1996, 87, 125-126.
12. Ivins, B. E., Pitt, M. L. M., Fellows, P. F., Farchaus, J.W. et al., Comparative efficacy of experimental anthrax vaccine candidates against inhalational anthrax in Rhesus macaques. Vaccine 1998, 16, 1141-1148.
13. Pitt, M. L. M., Little, S. F., Ivins, B. E., Fellows, P. F. et al., In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 2001, 19, 4768-4773.
14. Franken, K. L., Hiemstra, H. S., van Meijgaarden, K. E., Subronto, Y. et al., Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of the organic solvents. Protein Expr. Purif. 2000, 18, 95-99.
15. Reed, L. J., Muench, H., A simple method or estimating fifty percent end points. Am. J. Hyg. 1938, 27, 493-497.
16. Staats, H. F., Alam, S. M., Scearce, R. M., Kirwan, S.M. et al., In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect. Immun. 2007, 75, 5443-5452.
17. Food and Drug Administration (2002) New drug and biological drug products; Evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. 21CFR 314 and 601. U. S. Food and Drug Administration. Rockville, MD: Department of Health and Human Services.
18. Zaucha, G. M., Pitt, L. M., Estep, J., Ivins, B. E. et al., The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med. 1998, 122, 982-992.
19. Belton, F. C., Darlow, H. M., Henderson, D.W., The use of anthrax antigen to immunize man and monkey. Lancet 1956, 271, 476-479.
20. Wright, G. G., Green, T.W., Kanode, R. G. Jr., Studies on immunity in anthrax. V. Immunizing activity of alum-precipitated protective antigen. J. Immunol. 1954, 73, 387-391.
21. Wright, G. G., Puziss, M., Neely, W. B., Studies on immunity in anthrax. IX. Effect of variations in cultural conditions on elaboration of protective antigen by strains of Bacillus anthracis. J. Bacteriol. 1962, 83, 515-522.
22. Little, S. F., Ivins, B. E., Fellows, P. F., Pitt, M. L., et al., Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 2004, 22, 422-430.
23. Reuveny, S., White, M. D., Adar, Y. Y., Kafri, Y. et al., Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 2001, 69, 2888-2893.
24. Weiss, S., Kobiler, D., Levy, H., Marcus, H. et al., Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigenbased vaccine in rabbits. Infect. Immun. 2006, 74, 394-398.
25. Marcus, H., Danieli, R., Epstein, E., Velan, B. et al., Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect. Immun. 2004, 72, 3471-3477.
26. Williamson, E. D., Hodgson, I., Walker, N. J., Topping, A. W. et al., Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect. Immun. 2005, 73, 5978-5987.
27. Wimer-Mackin, S., Hinchcliffe, M., Petrie, C. R., Warwood, S. J. et al., An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 2006, 24, 3953-3963.
28. Welkos, S., Little, S., Friedlander, A., Fritz, D. et al., The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 2001, 147, 1677-1685.